These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 24577812

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response.
    Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jung ST, Jeon DG.
    J Orthop Sci; 2009 May; 14(3):292-7. PubMed ID: 19499296
    [Abstract] [Full Text] [Related]

  • 6. Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas.
    Amit P, Patro DK, Basu D, Elangovan S, Parathasarathy V.
    Am J Clin Oncol; 2014 Aug; 37(4):384-90. PubMed ID: 23388556
    [Abstract] [Full Text] [Related]

  • 7. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.
    Uhl M, Saueressig U, van Buiren M, Kontny U, Niemeyer C, Köhler G, Ilyasov K, Langer M.
    Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
    Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P.
    Cancer; 2006 Mar 01; 106(5):1154-61. PubMed ID: 16421923
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
    Rehan N, Bieling P, Winkler P, Helmke K, Maas R, Baldini N, Heise U, Fuchs N, Winkler K.
    Klin Padiatr; 1993 Mar 01; 205(4):200-9. PubMed ID: 8377444
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
    Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG.
    Ann Surg Oncol; 2008 Mar 01; 15(3):906-14. PubMed ID: 18163171
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin KH, Roh JK, Rha SY.
    Oncology; 2011 Mar 01; 80(1-2):107-17. PubMed ID: 21677455
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.